本文選題：H磁共振波譜 + 非小細(xì)胞肺癌　； 參考：《中國醫(yī)科大學(xué)學(xué)報(bào)》2017年12期

【摘要】：目的探討~1H磁共振波譜(~1H-MRS)在非小細(xì)胞肺癌(NSCLC)腦轉(zhuǎn)移放療療效評(píng)價(jià)中的預(yù)測價(jià)值。方法接受立體定向放療(SRT)聯(lián)合全腦照射(WBRT)的56例NSCLC腦轉(zhuǎn)移患者在治療前應(yīng)用~1H-MRS進(jìn)行檢查,測量Cho/Cr的比值,比較治療前Cho/Cr比值高組與Cho/Cr比值低組間療效的差異,分析~1H-MRS在NSCLC腦轉(zhuǎn)移放療療效評(píng)價(jià)中的預(yù)測價(jià)值。結(jié)果治療前Cho/Cr比值中位值為1.989。治療前Cho/Cr比值高組(1.989)1、3、5年生存率分別為29.3%(95%CI:11.3%~47.3%)、0%、0%,平均生存時(shí)間為9.77個(gè)月(95%CI:7.50~12.04個(gè)月)。Cho/Cr比值低組(1.989)1、3、5年生存率分別為70.5%(95%CI:53.3%~87.7%)、22.3%(95%CI:6.6%~38.0%)、1.8%(95%CI:0~8.1%),平均生存時(shí)間為24.67個(gè)月(95%CI:17.69~31.66個(gè)月)。治療前Cho/Cr比值高組與Cho/Cr比值低組比較平均生存時(shí)間有統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論 ~1H-MRS對(duì)NSCLC腦轉(zhuǎn)移放療的療效評(píng)價(jià)具有預(yù)測價(jià)值,治療前Cho/Cr比值高組預(yù)后差。
[Abstract]:Objective to evaluate the predictive value of 1H magnetic resonance spectroscopy (1H-MRS) in brain metastasis radiotherapy of NSCLC patients with non small cell lung cancer (NSCLC). Methods 56 patients with NSCLC brain metastasis received stereotactic radiotherapy combined with whole brain irradiation were examined with 1H-MRS before treatment, the ratio of Cho/Cr was measured, and the difference of curative effect between the high Cho/Cr ratio group and the low Cho/Cr ratio group before treatment was compared. To analyze the predictive value of 1 H Mrs in NSCLC brain metastasis radiotherapy. Results the median value of Cho/Cr ratio before treatment was 1.989. 娌葷枟鍓岰ho/Cr姣斿，

本文編號(hào)：1814762